Theravance Biopharma Inc (NASDAQ:TBPH) agreed to a sale to Zymeworks that values the stock ~22% above its March 3 close (and ~10% above recent VWAP) and includes a CVR for ampreloxetine, while a law firm launched a probe alleging the $17/share deal may raise securities‑law or fiduciary‑duty issues.
Previous Week Recap
- Theravance Biopharma Deal Valuation, CVR: Theravance Biopharma (TBPH) agreed to a deal valuing the stock about 22% above its March 3, 2026 close and ~10% above VWAP since then; includes a CVR for ampreloxetine.
- Law Firm Probes Theravance Sale: Law firm opened probe into Theravance Biopharma (TBPH) over its $17/share sale to Zymeworks, citing possible securities-law or fiduciary-duty issues and seeking higher consideration or disclosures.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.